Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Noa Biran, MD, John Theurer Cancer Center
Q&As
Step-Up Dosing for Multiple Myeloma Treatment in the Outpatient Setting
05/06/2024

Featuring Noa Biran, MD

Featuring Noa Biran, MD
Noa Biran, MD, explains the process of step-up dosing while transferring patients with multiple myeloma to an outpatient setting.
Noa Biran, MD, explains the process of step-up dosing while transferring patients with multiple myeloma to an outpatient setting.
Noa Biran, MD, explains the...
05/06/2024
Oncology
Noa Biran, MD, Hackensack Meridian Health
Conference Coverage
Evaluating Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma
05/06/2024

Featuring Noa Biran, MD

Featuring Noa Biran, MD
Noa Biran, MD, evaluates a variety of treatment options for patients with relapsed/refractory multiple myeloma at the 2024 Great Debates & Updates in Hematologic Malignancies meeting.
Noa Biran, MD, evaluates a variety of treatment options for patients with relapsed/refractory multiple myeloma at the 2024 Great Debates & Updates in Hematologic Malignancies meeting.
Noa Biran, MD, evaluates a...
05/06/2024
Oncology
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/19/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/19/2024
Lymphoma, Leukemia & Myeloma Network
Jia Ruan, MD, PhD, Weill Cornell Medicine
Conference Coverage
Evaluating Recent Study Findings on Treatment Combinations for Patients With MCL
04/19/2024

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Jia Ruan, MD, PhD, shares expert insight regarding recent and ongoing studies on treatment combinations for elderly and/or high-risk patients with mantle cell lymphoma.
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Jia Ruan, MD, PhD, shares expert insight regarding recent and ongoing studies on treatment combinations for elderly and/or high-risk patients with mantle cell lymphoma.
At the 2024 Great Debates &...
04/19/2024
Lymphoma, Leukemia & Myeloma Network
Jia Ruan, MD, PhD, Weill Cornell Medicine
Conference Coverage
Assessing Novel Non-Chemotherapy Agents as Initial Therapeutic Options for Patients With Mantle Cell Lymphoma
04/19/2024

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
At the 2024 Great Debates and Updates in Hematological Malignancies Meeting, Jia Ruan, MD, PhD, discusses the emergence of novel non-chemotherapy agents as initial therapeutic options for patients with mantle cell lymphoma, focusing on the...
At the 2024 Great Debates and Updates in Hematological Malignancies Meeting, Jia Ruan, MD, PhD, discusses the emergence of novel non-chemotherapy agents as initial therapeutic options for patients with mantle cell lymphoma, focusing on the...
At the 2024 Great Debates and...
04/19/2024
Lymphoma, Leukemia & Myeloma Network
Gareth Morgan, MD, NYU Langone Medical Center
Conference Coverage
Assessing the Strength of Minimal Residual Disease Testing for Patients With Multiple Myeloma
04/19/2024

Featuring Gareth Morgan, MD

Featuring Gareth Morgan, MD
Gareth Morgan, MD, argues in favor of using minimal residual disease testing for patients with multiple myeloma, which he discussed at the 2024 Great Debates & Updates in Hematologic Malignancies meeting.
Gareth Morgan, MD, argues in favor of using minimal residual disease testing for patients with multiple myeloma, which he discussed at the 2024 Great Debates & Updates in Hematologic Malignancies meeting.
Gareth Morgan, MD, argues in...
04/19/2024
Oncology
David Siegel, MD, PhD, Hackensack Meridian Health
Conference Coverage
Exploring the Role of Stem Cell Transplant for Patients With Myeloma Older Than 65
04/19/2024

Featuring David Siegel, MD, PhD

Featuring David Siegel, MD, PhD ...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, David Siegel, MD, PhD, discusses the role of stem cell transplant for patients with myeloma over age 65 and argues that it is a viable treatment option for this patient...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, David Siegel, MD, PhD, discusses the role of stem cell transplant for patients with myeloma over age 65 and argues that it is a viable treatment option for this patient...
At the 2024 Great Debates &...
04/19/2024
Oncology
Andrew Evens, DO, MBA, MSc, Rutgers Cancer Institute of New Jersey
Conference Coverage
Importance of Clinical Trials for Treatment Data in Hodgkin Lymphoma Research
04/18/2024

Featuring Andrew Evens, DO, MBA, MSc

Featuring Andrew Evens, DO, MBA, MSc ...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Evens, DO, MBA, MSc, emphasizes the importance of continuing clinical trials for patients with Hodgkin lymphoma to gather valuable treatment data.
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Evens, DO, MBA, MSc, emphasizes the importance of continuing clinical trials for patients with Hodgkin lymphoma to gather valuable treatment data.
At the 2024 Great Debates &...
04/18/2024
Lymphoma, Leukemia & Myeloma Network
Andrew Evens, DO, MBA, MSc, Rutgers Cancer Institute of New Jersey
Conference Coverage
Importance of Individualized Therapy, Prognostication, and Prediction in the Treatment of Hodgkin Lymphoma
04/16/2024

Featuring Andrew Evens, DO, MBA, MSc

Featuring Andrew Evens, DO, MBA, MSc ...
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Andrew Evens, DO, MBA, MSc, speaks on the importance of targeted therapy, prognostication, and prediction when treating patients with Hodgkin lymphoma.
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Andrew Evens, DO, MBA, MSc, speaks on the importance of targeted therapy, prognostication, and prediction when treating patients with Hodgkin lymphoma.
During the 2024 Great Debates &...
04/16/2024
Oncology
Brea Lipe, University of Rochester Medical Center
Conference Coverage
Should the Sequencing of BCMA-Directed Therapy be Used in Multiple Myeloma Treatment?
04/16/2024

Featuring Brea Lipe, MD

Featuring Brea Lipe, MD
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Brea Lipe, MD, argues against the utilization of sequencing BCMA-directed therapies as a treatment regimen for patients with multiple myeloma.
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Brea Lipe, MD, argues against the utilization of sequencing BCMA-directed therapies as a treatment regimen for patients with multiple myeloma.
During the 2024 Great Debates &...
04/16/2024
Oncology
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Ashley Rosko, MD
Conference Coverage
Factors to Consider When Treating Patients With Multiple Myeloma With Bispecific Antibodies in an Outpatient Setting
04/10/2024

Featuring Ashley Rosko, MD

Featuring Ashley Rosko, MD
Ashley Rosko, MD, discusses factors to consider when administering bispecific antibody therapy to patients with multiple myeloma in an outpatient setting, which she discussed at the 2024 Great Debates & Updates in Hematologic Malignancies...
Ashley Rosko, MD, discusses factors to consider when administering bispecific antibody therapy to patients with multiple myeloma in an outpatient setting, which she discussed at the 2024 Great Debates & Updates in Hematologic Malignancies...
Ashley Rosko, MD, discusses...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Aditi Shastri, MD, Montefiore Einstein Comprehensive Cancer Center
Conference Coverage
Recent Updates in Risk Stratification and Treatment Methods for Patients With MDS
04/10/2024

Featuring Aditi Shastri, MD

Featuring Aditi Shastri, MD
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Aditi Shastri, MD, shares expert insight on recent updates in risk stratification and treatment regimens for patients with low to intermediate risk myelodysplastic...
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Aditi Shastri, MD, shares expert insight on recent updates in risk stratification and treatment regimens for patients with low to intermediate risk myelodysplastic...
During the 2024 Great Debates &...
04/10/2024
Oncology
Joseph Mikhael, MD, MEd, FRCPC, FACP
Conference Coverage
Is Quadruplet Therapy the New Standard of Care for Patients With Multiple Myeloma?
04/10/2024

Featuring Joseph Mikhael, MD, MEd, FRCPC, FACP

Featuring Joseph Mikhael, MD, MEd, FR...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, evaluates whether or not quadruplet therapy should be the new standard-of-care treatment for patients with multiple myeloma who are...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, evaluates whether or not quadruplet therapy should be the new standard-of-care treatment for patients with multiple myeloma who are...
At the 2024 Great Debates &...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Joseph Mikhael, MD, City of Hope Cancer Center
Conference Coverage
Choosing Between CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma Treatment
04/09/2024

Featuring Joseph Mikhael, MD, MEd, FRCPC, FACP

Featuring Joseph Mikhael, MD, MEd, FR...
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, shares expert insight on when to choose CAR-T therapy versus bispecific antibodies in multiple myeloma treatment.
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, shares expert insight on when to choose CAR-T therapy versus bispecific antibodies in multiple myeloma treatment.
During the 2024 Great Debates &...
04/09/2024
Lymphoma, Leukemia & Myeloma Network
Jessica Altman, MD
Conference Coverage
Sequential Therapy vs Triplet Therapy for Patients With Newly Diagnosed AML Ineligible for Intensive Chemotherapy
04/09/2024

Featuring Jessica Altman, MD

Featuring Jessica Altman, MD
During the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Jessica Altman, MD, argues in favor of using sequential therapy over triplet therapy for patients with newly diagnosed acute myeloid leukemia who are ineligible for...
During the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Jessica Altman, MD, argues in favor of using sequential therapy over triplet therapy for patients with newly diagnosed acute myeloid leukemia who are ineligible for...
During the 2024 Great Debates &...
04/09/2024
Oncology
Ashley Rosko, MD
Conference Coverage
Analyzing Comprehensive Health of Patients With Multiple Myeloma for Transplant Decision-Making
04/08/2024

Featuring Ashley Rosko, MD

Featuring Ashley Rosko, MD
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Ashley Rosko, MD, discusses why the comprehensive health of patients with multiple myeloma should be analyzed to make transplant decisions, rather than only focusing on...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Ashley Rosko, MD, discusses why the comprehensive health of patients with multiple myeloma should be analyzed to make transplant decisions, rather than only focusing on...
At the 2024 Great Debates &...
04/08/2024
Oncology
Andrew Yee, MD
Conference Coverage
Mitigating Risk of Infection While Using BCMA Bispecific Antibodies as Treatment
04/08/2024

Featuring Andrew Yee, MD

Featuring Andrew Yee, MD
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Yee, MD, speaks about mitigating the risks of infection while using BCMA bispecific antibodies as treatment.
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Yee, MD, speaks about mitigating the risks of infection while using BCMA bispecific antibodies as treatment.
At the 2024 Great Debates &...
04/08/2024
Lymphoma, Leukemia & Myeloma Network
Andrew Yee, MD
Conference Coverage
Should Additional BCMA Therapy be Utilized After Previous BCMA Therapy?
04/08/2024

Featuring Andrew Yee, MD

Featuring Andrew Yee, MD
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Yee, MD, discusses whether or not it is suitable for a patient to receive additional BCMA therapy after previous BCMA therapy.
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Yee, MD, discusses whether or not it is suitable for a patient to receive additional BCMA therapy after previous BCMA therapy.
At the 2024 Great Debates &...
04/08/2024
Oncology
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Influence of Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia
04/06/2024

Featuring John Allan, MD

Featuring John Allan, MD
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, John Allan, MD, shares expert insight on the impact targeted agents have in the treatment of CLL, focusing particularly on frontline therapy.
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, John Allan, MD, shares expert insight on the impact targeted agents have in the treatment of CLL, focusing particularly on frontline therapy.
At the 2024 Great Debates &...
04/06/2024
Oncology
Samuel Yamshon, MD
Conference Coverage
Examining the Efficacy of CAR T-Cell Therapy Among Elderly Patients With R/R DLBCL
04/06/2024

Featuring Samuel Yamshon, MD

Featuring Samuel Yamshon, MD
During the Great Debates & Updates in Hematologic Malignancies meeting, Samuel Yamshon, MD, examines the efficacy of using CAR T-cell therapy to treat elderly patients with relapsed/refractory diffuse large B-cell lymphoma.
During the Great Debates & Updates in Hematologic Malignancies meeting, Samuel Yamshon, MD, examines the efficacy of using CAR T-cell therapy to treat elderly patients with relapsed/refractory diffuse large B-cell lymphoma.
During the Great Debates &...
04/06/2024
Oncology
Peter Martin, MD
Conference Coverage
Using Lenalidomide and Rituximab, Tazemetostat, or Bispecific Antibodies to Treat Patients With Follicular Lymphoma
04/06/2024

Featuring Peter Martin, MD

Featuring Peter Martin, MD
During the 2024 Great Debates & Updates in Hematologic Malignancies meeting in New York, Peter Martin, MD, argued in favor of alternative treatment regimens over CAR T-cell therapy for treating follicular lymphoma.
During the 2024 Great Debates & Updates in Hematologic Malignancies meeting in New York, Peter Martin, MD, argued in favor of alternative treatment regimens over CAR T-cell therapy for treating follicular lymphoma.
During the 2024 Great Debates &...
04/06/2024
Oncology
Jia Ruan, MD, PhD
Active Evaluations and Topics of Interest Within the MCL Treatment Landscape
04/06/2024

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
Jia Ruan, MD, PhD, shares various active evaluations and topics of interest within the MCL treatment landscape, including the comparison between novel combinations versus traditional chemoimmunotherapy.
Jia Ruan, MD, PhD, shares various active evaluations and topics of interest within the MCL treatment landscape, including the comparison between novel combinations versus traditional chemoimmunotherapy.
Jia Ruan, MD, PhD, shares...
04/06/2024
Lymphoma, Leukemia & Myeloma Network
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Is There a Role for Chemo-Immunotherapy in the CLL Treatment Landscape?
04/06/2024

Featuring John Allan, MD

Featuring John Allan, MD
At the 2024 Great Debates & Updates Meeting in Hematological Malignancies in New York, John Allan, MD, discusses if there is a role for chemo-immunotherapy in the CLL treatment landscape.
At the 2024 Great Debates & Updates Meeting in Hematological Malignancies in New York, John Allan, MD, discusses if there is a role for chemo-immunotherapy in the CLL treatment landscape.
At the 2024 Great Debates &...
04/06/2024
Lymphoma, Leukemia & Myeloma Network
Joshua Richter, MD
Conference Coverage
Exploring Promising Novel Advances in the Multiple Myeloma Treatment Landscape
04/05/2024

Featuring Joshua Richter, MD

Featuring Joshua Richter, MD
Joshua Richter, MD, discusses promising novel advances in the multiple myeloma treatment landscape, including the use of T-cell redirection therapy and possible treatment approvals to come.
Joshua Richter, MD, discusses promising novel advances in the multiple myeloma treatment landscape, including the use of T-cell redirection therapy and possible treatment approvals to come.
Joshua Richter, MD, discusses...
04/05/2024
Lymphoma, Leukemia & Myeloma Network
Joshua Richter, MD
Conference Coverage
Should MRD-Based Decision-Making be Utilized in Multiple Myeloma Treatment Strategies?
04/05/2024

Featuring Joshua Richter, MD

Featuring Joshua Richter, MD
At the 2024 Great Debates & Updates in Hematologic Malignancies, Joshua Richter, MD, explores the role of minimal residual disease in multiple myeloma treatment strategies, addressing whether it should be used to make clinical decisions for...
At the 2024 Great Debates & Updates in Hematologic Malignancies, Joshua Richter, MD, explores the role of minimal residual disease in multiple myeloma treatment strategies, addressing whether it should be used to make clinical decisions for...
At the 2024 Great Debates &...
04/05/2024
Lymphoma, Leukemia & Myeloma Network
Andrew Yee, MD
Videos
Novel Developments in the Multiple Myeloma Treatment Landscape
09/15/2023

Featuring Andrew Yee, MD

Featuring Andrew Yee, MD
Andrew Yee, MD, discusses new developments and possibilities in the treatment landscape for patients with multiple myeloma at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.
Andrew Yee, MD, discusses new developments and possibilities in the treatment landscape for patients with multiple myeloma at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.
Andrew Yee, MD, discusses new...
09/15/2023
Oncology
Andrew Evens, DO, MBA, MSc
Videos
Predicting Long-Term Effects Among Patients Treated for Early-Stage Hodgkin Lymphoma
09/07/2023

Featuring Andrew Evens, DO, MBA, MSc

Featuring Andrew Evens, DO, MBA, MSc ...
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Evens, DO, MBA, MSc, discusses the management and prediction of long-term effects among patients treated for early-stage Hodgkin lymphoma.
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Evens, DO, MBA, MSc, discusses the management and prediction of long-term effects among patients treated for early-stage Hodgkin lymphoma.
At the 2023 Great Debates &...
09/07/2023
Oncology
Monique Hartley Brown, MD, MMSc
Videos
Initiating Improvements in Access and Diversity in Clinical Trials for Patients With Multiple Myeloma
09/07/2023

Featuring Monique Hartley-Brown, MD, MMSc

Featuring Monique Hartley-Brown, MD, ...
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Monique Hartley-Brown, MD, MMSc, discusses initiatives to improve diversity and accessibility in clinical trials for patients with MM.
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Monique Hartley-Brown, MD, MMSc, discusses initiatives to improve diversity and accessibility in clinical trials for patients with MM.
At the 2023 Great Debates &...
09/07/2023
Oncology
Andrew Yee, MD
Videos
Selecting Optimal Treatments for Patients With Relapsed Multiple Myeloma
09/06/2023

Featuring Andrew Yee, MD

Featuring Andrew Yee, MD
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Yee, MD, discusses treatment options for patients with relapsed MM, including anti-CD38 antibodies, cyclophosphamide-based combinations, and BCL-2 inhibitors.
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Yee, MD, discusses treatment options for patients with relapsed MM, including anti-CD38 antibodies, cyclophosphamide-based combinations, and BCL-2 inhibitors.
At the 2023 Great Debates &...
09/06/2023
Oncology
Andrew Evens, DO, MBA, MSc
Videos
Antibody Drug Conjugates for the Frontline Treatment of Patients With Advanced-Stage Hodgkin Lymphoma
09/05/2023

Featuring Andrew Evens, DO, MBA, MSc

Featuring Andrew Evens, DO, MBA, MSc ...
Andrew Evens, DO, MBA, MSc, analyzes the first-line treatment landscape for patients with advanced-stage Hodgkin lymphoma through the integration of antibody drug conjugates, at the 2023 Great Debates & Updates in Hematologic Malignancies...
Andrew Evens, DO, MBA, MSc, analyzes the first-line treatment landscape for patients with advanced-stage Hodgkin lymphoma through the integration of antibody drug conjugates, at the 2023 Great Debates & Updates in Hematologic Malignancies...
Andrew Evens, DO, MBA, MSc,...
09/05/2023
Oncology
Daniel DeAngelo, MD, PhD
Videos
Promising Outcomes of FGFR1 Inhibitor Pemigatinib for Myeloid Lymphoid Neoplasms
08/28/2023

Featuring Daniel DeAngelo, MD, PhD

Featuring Daniel DeAngelo, MD, PhD ...
Daniel DeAngelo, MD, PhD, presents data on the promising outcomes of pemigatinib, an FGFR1 inhibitor, among patients with myeloid lymphoid neoplasms, at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.
Daniel DeAngelo, MD, PhD, presents data on the promising outcomes of pemigatinib, an FGFR1 inhibitor, among patients with myeloid lymphoid neoplasms, at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.
Daniel DeAngelo, MD, PhD,...
08/28/2023
Oncology
Peter Voorhees, MD
Videos
Examining CD38-Targeting Antibody Therapies for Patients With Newly Diagnosed Transplant-Ineligible Multiple Myeloma
08/28/2023

Featuring Peter Voorhees, MD

Featuring Peter Voorhees, MD
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Peter Voorhees, MD, analyzes data on the use of CD38-targeting antibodies for patients with newly diagnosed transplant-ineligible multiple myeloma.
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Peter Voorhees, MD, analyzes data on the use of CD38-targeting antibodies for patients with newly diagnosed transplant-ineligible multiple myeloma.
At the 2023 Great Debates &...
08/28/2023
Oncology
Andrew Evens, DO, MBA, MSc
Videos
Current Treatment Landscape for Patients With Relapsed/Refractory Hodgkin Lymphoma
08/24/2023

Featuring Andrew Evens, DO, MBA, MSc

Featuring Andrew Evens, DO, MBA, MSc ...
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Evens, DO, MBA, MSc, discusses current treatment options for patients with Hodgkin lymphoma after relapse occurs.
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Evens, DO, MBA, MSc, discusses current treatment options for patients with Hodgkin lymphoma after relapse occurs.
At the 2023 Great Debates &...
08/24/2023
Oncology
Monique Hartley-Brown, MD, MMSc
Videos
Emergent Therapies for Patients With Relapsed/Refractory Multiple Myeloma
08/24/2023

Featuring Monique Hartley-Brown, MD, MMSc

Featuring Monique Hartley-Brown, MD, ...
Monique Hartley-Brown, MD, MMSc, presents her insights into treatment developments for patients with relapsed/refractory multiple myeloma, a topic which she discussed at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.
Monique Hartley-Brown, MD, MMSc, presents her insights into treatment developments for patients with relapsed/refractory multiple myeloma, a topic which she discussed at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.
Monique Hartley-Brown, MD, MMSc,...
08/24/2023
Oncology
Amir Fathi, MD
Videos
Incorporating IDH and Menin Inhibitors as Therapies for Subsets of Patients With AML
08/22/2023

Featuring Amir Fathi, MD

Featuring Amir Fathi, MD
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Amir Fathi, MD, shares insights on the emergence of IDH and menin inhibitors as therapies to target certain subsets of patients with acute myeloid leukemia.
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Amir Fathi, MD, shares insights on the emergence of IDH and menin inhibitors as therapies to target certain subsets of patients with acute myeloid leukemia.
At the 2023 Great Debates &...
08/22/2023
Oncology
Peter Voorhees, MD
Videos
Evolving Frontline Therapies for Patients With Newly Diagnosed Multiple Myeloma
08/22/2023

Featuring Peter Voorhees, MD

Featuring Peter Voorhees, MD
Peter Voorhees, MD, discusses the latest updates in frontline therapeutic options for patients with newly diagnosed MM, a topic which he presented on at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.
Peter Voorhees, MD, discusses the latest updates in frontline therapeutic options for patients with newly diagnosed MM, a topic which he presented on at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.
Peter Voorhees, MD, discusses...
08/22/2023
Oncology
Amer Zeidan, MBBS
Videos
New Developments in Risk Stratification and Management of High-Risk and Low-Risk MDS
08/19/2023

Featuring Amer Zeidan, MBBS

Featuring Amer Zeidan, MBBS
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Amer Zeidan, MBBS, speaks on recent developments in risk stratification and treatment management among patients with high-risk and low-risk myelodysplastic syndromes.
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Amer Zeidan, MBBS, speaks on recent developments in risk stratification and treatment management among patients with high-risk and low-risk myelodysplastic syndromes.
At the 2023 Great Debates &...
08/19/2023
Oncology
Daniel DeAngelo, MD, PhD
Videos
Diagnosing and Treating Patients With Indolent and Advanced Systemic Mastocytosis
08/19/2023

Featuring Daniel DeAngelo, MD, PhD

Featuring Daniel DeAngelo, MD, PhD ...
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Daniel DeAngelo, MD, PhD, shares insights into recent treatment developments and diagnostic criteria for patients with indolent and systemic mastocytosis.
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Daniel DeAngelo, MD, PhD, shares insights into recent treatment developments and diagnostic criteria for patients with indolent and systemic mastocytosis.
At the 2023 Great Debates &...
08/19/2023
Oncology
John Allan, MD
Videos
Analyzing the Role of BTK Inhibitors and Combination Therapies in the Frontline Treatment of Patients With CLL
08/18/2023

Featuring John Allan, MD

Featuring John Allan, MD
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, John Allan, MD, analyzes the role of BTK inhibitors and combination therapies in the frontline treatment of patients with chronic lymphocytic leukemia.
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, John Allan, MD, analyzes the role of BTK inhibitors and combination therapies in the frontline treatment of patients with chronic lymphocytic leukemia.
At the 2023 Great Debates &...
08/18/2023
Oncology
Carla Casulo, MD
Videos
Choosing Treatment Options and Managing Toxicities for Patients With R/R Follicular Lymphoma
08/18/2023

Featuring Carla Casulo, MD

Featuring Carla Casulo, MD
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Carla Casulo, MD, summarizes the available treatment options for relapsed/refractory follicular lymphoma and options for managing various treatment-related toxicities.
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Carla Casulo, MD, summarizes the available treatment options for relapsed/refractory follicular lymphoma and options for managing various treatment-related toxicities.
At the 2023 Great Debates &...
08/18/2023
Oncology
Elizabeth Brem, MD
Videos
Individualized Treatment Approaches for Patients With Hodgkin Lymphoma
08/18/2023

Featuring Elizabeth Brem, MD

Featuring Elizabeth Brem, MD
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Elizabeth Brem, MD, provides insights into treatment approaches used for cases of patients with Hodgkin lymphoma.
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Elizabeth Brem, MD, provides insights into treatment approaches used for cases of patients with Hodgkin lymphoma.
At the 2023 Great Debates &...
08/18/2023
Oncology
C. Ola Landgren, MD
Videos
Should ASCT be Standard of Care for Frontline Treatment of Patients With Multiple Myeloma?
05/15/2023
C. Ola Landgren, MD, PhD, participated in a debate on whether melphalan plus ASCT after induction therapy should continue to be the standard of care in frontline treatment of patients with multiple myeloma.
C. Ola Landgren, MD, PhD, participated in a debate on whether melphalan plus ASCT after induction therapy should continue to be the standard of care in frontline treatment of patients with multiple myeloma.
C. Ola Landgren, MD, PhD,...
05/15/2023
Oncology
Amrita Krishnan, MD
Videos
ASCT as the Continued Standard of Care in Frontline Multiple Myeloma Therapy
05/10/2023
Amrita Krishnan, MD, participated in a debate about whether high-dose chemotherapy followed by autologous stem cell transplant after completion of induction therapy is the optimal frontline therapy for patients with multiple myeloma.
Amrita Krishnan, MD, participated in a debate about whether high-dose chemotherapy followed by autologous stem cell transplant after completion of induction therapy is the optimal frontline therapy for patients with multiple myeloma.
Amrita Krishnan, MD,...
05/10/2023
Oncology
Michael Rosenzweig, MD
Videos
Strategies for Diagnosing and Treating Patients With Amyloidosis
05/10/2023
Michael Rosenzweig, MD, shares insights on strategies for diagnosing and treating patients with various subtypes of amyloidosis.
Michael Rosenzweig, MD, shares insights on strategies for diagnosing and treating patients with various subtypes of amyloidosis.
Michael Rosenzweig, MD, shares...
05/10/2023
Oncology
Matthew Matasar MD
Videos
Increasing Quality of Life Using Survivorship-Focused Care for Patients With Hodgkin and Non-Hodgkin Lymphoma
05/05/2023
At the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Matthew Matasar, MD, discussed the importance of utilizing survivorship-focused care models and increasing the quality of life of lymphoma...
At the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Matthew Matasar, MD, discussed the importance of utilizing survivorship-focused care models and increasing the quality of life of lymphoma...
At the 2023 Great Debates &...
05/05/2023
Oncology
John Mascarenhas, MD
Videos
Recent Advancements in Clinical Development for the Treatment of Myelofibrosis
05/04/2023
At the 2023 Great Debates & Updates in Hematologic Malignancies conference, New York, John Mascarenhas, MD, discussed recent advancements in clinical developments for the treatment of myeloproliferative neoplasms, specifically myelofibrosis,...
At the 2023 Great Debates & Updates in Hematologic Malignancies conference, New York, John Mascarenhas, MD, discussed recent advancements in clinical developments for the treatment of myeloproliferative neoplasms, specifically myelofibrosis,...
At the 2023 Great Debates &...
05/04/2023
Oncology
Joshua Richter, MD
Videos
Optimization of Therapies for Older or More Frail Patients With Multiple Myeloma
05/04/2023
At the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Joshua Richter, MD, discussed the optimization of therapies for older and more frail patients with multiple myeloma.
At the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Joshua Richter, MD, discussed the optimization of therapies for older and more frail patients with multiple myeloma.
At the 2023 Great Debates &...
05/04/2023
Oncology
Adam Olszewski MD Brown University
Videos
Role of CNS Prophylaxis in Aggressive B-Cell Lymphoma Treatment
05/03/2023
Adam Olszewski, MD, debates that CNS prophylaxis has a valuable role in the treatment of aggressive B-cell lymphomas such as diffuse large B-cell lymphoma.
Adam Olszewski, MD, debates that CNS prophylaxis has a valuable role in the treatment of aggressive B-cell lymphomas such as diffuse large B-cell lymphoma.
Adam Olszewski, MD, debates that...
05/03/2023
Oncology
Peter Voorhees, MD
Videos
Choosing the Optimal Treatment for Patients With Newly Diagnosed Multiple Myeloma
05/03/2023
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Peter M. Voorhees, MD, shared strategies for selecting a frontline therapy for patients with multiple myeloma.
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Peter M. Voorhees, MD, shared strategies for selecting a frontline therapy for patients with multiple myeloma.
At the 2023 Great Debates &...
05/03/2023
Oncology
Joseph Mikhael, MD
Videos
Strategies for Treating Patients With Multiple Myeloma in Early Relapse
05/02/2023
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting in New York, New York, Joseph Mikhael, MD, shared strategies for treating patients with multiple myeloma in early relapse.
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting in New York, New York, Joseph Mikhael, MD, shared strategies for treating patients with multiple myeloma in early relapse.
At the 2023 Great Debates &...
05/02/2023
Oncology
Melissa Alsina, MD, Moffitt Cancer Center
Videos
Looking to the Future of Treatment Options for Patients With Multiple Myeloma
05/02/2023
At the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Melissa Alsina, MD, discussed possible future treatment options for patients with myeloma.
At the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Melissa Alsina, MD, discussed possible future treatment options for patients with myeloma.
At the 2023 Great Debates &...
05/02/2023
Oncology
Saad Usmani Memorial Sloan Kettering Cancer Center
Videos
Novel and Cellular Therapies to Treat Patients With R/R Multiple Myeloma
05/02/2023
At the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Saad Z. Usmani, MD, MBA, FACP, discussed novel and cellular therapies used to treat relapsed/refractory multiple myeloma, including but not...
At the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Saad Z. Usmani, MD, MBA, FACP, discussed novel and cellular therapies used to treat relapsed/refractory multiple myeloma, including but not...
At the 2023 Great Debates &...
05/02/2023
Oncology
Andrew Artz MD City of Hope
Videos
Benefits of HSCT for Patients With AML With MRD After Initial Therapy
04/27/2023
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting in New York, New York, Andrew Artz, MD, participated in a debate about the benefits of hematopoietic stem cell transplantation among patients with AML with MRD after...
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting in New York, New York, Andrew Artz, MD, participated in a debate about the benefits of hematopoietic stem cell transplantation among patients with AML with MRD after...
At the 2023 Great Debates &...
04/27/2023
Oncology
Amer Zeidan Yale Cancer Center
Videos
Effective Risk Stratification for Patients With Myelodysplastic Syndromes
04/26/2023
At the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Amer Zeidan, MBBS, MHS, discussed effective risk stratification among patients with myelodysplastic syndromes.
At the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Amer Zeidan, MBBS, MHS, discussed effective risk stratification among patients with myelodysplastic syndromes.
At the 2023 Great Debates &...
04/26/2023
Oncology
Richard Stone, MD
Videos
Considering MRD Before HSCT for Patients With Acute Myeloid Leukemia
04/25/2023
At the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, Richard Stone, MD, debated the role of measurable residual disease when considering hematopoietic stem cell transplantation for patients with acute...
At the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, Richard Stone, MD, debated the role of measurable residual disease when considering hematopoietic stem cell transplantation for patients with acute...
At the 2023 Great Debates &...
04/25/2023
Oncology
Elizabeth Brem University of California Irvine
Videos
Analyzing Patient Selection and the Utility of CNS Prophylaxis for Patients With DLBCL
04/20/2023
In a debate at the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Elizabeth A. Brem, MD, analyzed the role of central nervous system prophylaxis for patients with DLBCL.
In a debate at the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Elizabeth A. Brem, MD, analyzed the role of central nervous system prophylaxis for patients with DLBCL.
In a debate at the 2023 Great...
04/20/2023
Oncology
Jennifer Amengual, MD, Columbia University
Videos
Choosing Treatment Options for Patients With R/R DLBCL Ineligible for CAR T-Cell Therapy
04/18/2023
At the 2023 Great Debates & Updates in Hematologic Malignancies in New York, New York, Jennifer Amengual, MD, discussed the process of choosing among non-CAR-T options for patients with recurrent aggressive lymphoma, particularly DLBCL.
At the 2023 Great Debates & Updates in Hematologic Malignancies in New York, New York, Jennifer Amengual, MD, discussed the process of choosing among non-CAR-T options for patients with recurrent aggressive lymphoma, particularly DLBCL.
At the 2023 Great Debates &...
04/18/2023
Oncology
John Leonard, MD, Weill Cornell Medicine
Videos
New Developments in First- and Second-Line Treatments for Patients With Aggressive DLBCL
06/24/2022
John Leonard, MD, discusses recent therapeutic developments for aggressive DLBCL in the first- and second-line treatment settings, highlighting recent data around pelotuzumab vedotin and CAR-T therapies.
John Leonard, MD, discusses recent therapeutic developments for aggressive DLBCL in the first- and second-line treatment settings, highlighting recent data around pelotuzumab vedotin and CAR-T therapies.
John Leonard, MD, discusses...
06/24/2022
Oncology
Tycel Phillips, MD
Videos
Treatment Approaches for Patients With Untreated and Relapsed MCL
05/23/2022
Tycel Phillips, MD, reviews standard therapies utilized for patients with MCL, including nonaggressive regimens and BTK inhibitor therapies.
Tycel Phillips, MD, reviews standard therapies utilized for patients with MCL, including nonaggressive regimens and BTK inhibitor therapies.
Tycel Phillips, MD, reviews...
05/23/2022
Oncology
Sarah Rutherford, MD, Weill Cornell Medicine
Videos
CAR-T Therapy vs Other Novel Agents for Third-Line Treatment of FL
05/22/2022
Sarah Rutherford, MD, debates why she believes CAR-T therapy is the preferred treatment for patients with early progressing FL after 2 lines of prior therapy.
Sarah Rutherford, MD, debates why she believes CAR-T therapy is the preferred treatment for patients with early progressing FL after 2 lines of prior therapy.
Sarah Rutherford, MD, debates...
05/22/2022
Oncology
Conference Coverage
Pomalidomide vs Carfilzomib for Patients With MM at First Relapse
03/25/2022

Janelle Bradley

Janelle Bradley
Nina Shah, MD, argues in favor of pomalidomide over carfilzomib for patients with MM at first relapse in the real-world setting at the 2022 Great Debates and Updates in Hematologic Malignancies meeting.
Nina Shah, MD, argues in favor of pomalidomide over carfilzomib for patients with MM at first relapse in the real-world setting at the 2022 Great Debates and Updates in Hematologic Malignancies meeting.
Nina Shah, MD, argues in favor...
03/25/2022
Oncology
Conference Insider
Dr Shah Highlights Benefits of Pomalidomide in Patients With MM
03/25/2022
Nina Shah, MD, presents pomalidomide as a superior treatment versus carfilzomib for patients with MM during the virtual Great Debates & Updates in Hematologic Malignancies.
Nina Shah, MD, presents pomalidomide as a superior treatment versus carfilzomib for patients with MM during the virtual Great Debates & Updates in Hematologic Malignancies.
Nina Shah, MD, presents...
03/25/2022
Oncology
Conference Insider
Dr Martin Discusses How to Approach MCL
03/23/2022

Emily Bader

Emily Bader
Peter Martin, MD, discusses how to approach MCL, including what’s been learned so far and what’s to be expected, at the virtual Great Debates & Updates in Hematologic Malignancies.
Peter Martin, MD, discusses how to approach MCL, including what’s been learned so far and what’s to be expected, at the virtual Great Debates & Updates in Hematologic Malignancies.
Peter Martin, MD, discusses how...
03/23/2022
Oncology
Conference Insider
Dr Leonard Highlights Crucial New Data, Practice Changing Therapies in DLBCL
03/23/2022

Alexa Stoia

Alexa Stoia
John Leonard, MD, presents novel data with CAR-T therapies in upfront, second line DLBCL during the virtual Great Debates & Updates in Hematologic Malignancies.
John Leonard, MD, presents novel data with CAR-T therapies in upfront, second line DLBCL during the virtual Great Debates & Updates in Hematologic Malignancies.
John Leonard, MD, presents novel...
03/23/2022
Oncology
luger
Conference Insider
Dr Luger Shares Refined Prognosis and Detection Methods of MRD in ALL
07/27/2021
MRD has been shown to be a viable assessment indicator for disease outcomes in patients with ALL, according to Selina Luger, MD.
MRD has been shown to be a viable assessment indicator for disease outcomes in patients with ALL, according to Selina Luger, MD.
MRD has been shown to be a...
07/27/2021
Oncology
dr erba
Conference Insider
Harry Erba, Md, PhD, Discusses Treatment Shift in AML with Maintenance Therapy
07/16/2021
Harry Erba, MD, PhD, discusses how the treatment paradigm for AML has changed with maintenance therapy.
Harry Erba, MD, PhD, discusses how the treatment paradigm for AML has changed with maintenance therapy.
Harry Erba, MD, PhD, discusses...
07/16/2021
Oncology
jw
Interview
Jennifer Woyach, MD, Discusses How to Best Sequence Regimens for Patients with R/R CLL
07/15/2021
Jennifer Woyach, MD, shares an update on how to best sequence available regimens for the management of patients with R/R CLL.
Jennifer Woyach, MD, shares an update on how to best sequence available regimens for the management of patients with R/R CLL.
Jennifer Woyach, MD, shares an...
07/15/2021
Oncology
dra
Conference Insider
Jennifer Amengual, MD, Shares Updates in the Treatment of T-Cell Lymphomas
07/15/2021
Treatment options for T-cell lymphoma show progress in biologic understanding of epigenetic mutations, prognosis, and toxicity stratifications, according to Dr Amengual.
Treatment options for T-cell lymphoma show progress in biologic understanding of epigenetic mutations, prognosis, and toxicity stratifications, according to Dr Amengual.
Treatment options for T-cell...
07/15/2021
Oncology
Conference Insider
Dr Rajkumar Talks Frontline Therapy of Myeloma for Transplant-Ineligible Patients
03/02/2021
At the virtual Great Debates & Updates in Hematologic Malignancies, S. Vincent Rajkumar, MD, discussed the frontline therapy of MM for transplant-ineligible patients.
At the virtual Great Debates & Updates in Hematologic Malignancies, S. Vincent Rajkumar, MD, discussed the frontline therapy of MM for transplant-ineligible patients.
At the virtual Great Debates &...
03/02/2021
Oncology
Conference Insider
Naveen Pemmaraju, MD, Provides an Overview of Novel Therapies for MPNs
03/01/2021
During the virtual Great Debates & Updates in Hematologic Malignancies, Dr Pemmaraju discussed new therapies for myeloproliferative neoplasms (MPNs) with a focus on CMML.
During the virtual Great Debates & Updates in Hematologic Malignancies, Dr Pemmaraju discussed new therapies for myeloproliferative neoplasms (MPNs) with a focus on CMML.
During the virtual Great Debates...
03/01/2021
Oncology
Conference Insider
Joseph Mikhael, MD, Discusses Emerging Therapies in MM
02/26/2021
At the virtual Great Debates & Updates in Hematologic Malignancies, Dr Mikhael presented emerging therapies in multiple myeloma (MM).
At the virtual Great Debates & Updates in Hematologic Malignancies, Dr Mikhael presented emerging therapies in multiple myeloma (MM).
At the virtual Great Debates &...
02/26/2021
Oncology
Conference Insider
Jonathon Cohen, MD, Talks Treatment Options for MCL
02/26/2021
At the virtual Great Debates & Updates in Hematologic Malignancies, Jonathon Cohen, MD, presented standard treatment regiments and novel agents for the treatment of MCL.
At the virtual Great Debates & Updates in Hematologic Malignancies, Jonathon Cohen, MD, presented standard treatment regiments and novel agents for the treatment of MCL.
At the virtual Great Debates &...
02/26/2021
Oncology
Elias Jabbour, MD, Talks About the Management of Ph+ and Ph-like ALL
Podcasts
Elias Jabbour, MD, Talks About the Management of Ph+ and Ph-like ALL
08/28/2020
Dr Jabbour discusses his presentation from the virtual Great Debates and Updates in Hematologic Malignancies on the management of patients with Ph+ and Ph-like ALL.
Dr Jabbour discusses his presentation from the virtual Great Debates and Updates in Hematologic Malignancies on the management of patients with Ph+ and Ph-like ALL.
Dr Jabbour discusses his...
08/28/2020
Oncology
News
Michael Mauro, MD, Talks ELN/NCCN Recommendations for Patients With CML
07/18/2020
At the virtual Great Debates & Updates in Hematologic Malignancies, Michael Mauro, MD, presented on practical approaches for monitoring patients with CML as per NCCN and ELN recommendations.
At the virtual Great Debates & Updates in Hematologic Malignancies, Michael Mauro, MD, presented on practical approaches for monitoring patients with CML as per NCCN and ELN recommendations.
At the virtual Great Debates &...
07/18/2020
Oncology
Conference Insider
Challenges and New Horizons in the Treatment of Patients With AML
07/17/2020
During the Great Debates & Updates in Hematologic Malignancies, Gail Roboz, MD, discussed how clinicians can lead patients with AML down the correct treatment path.
During the Great Debates & Updates in Hematologic Malignancies, Gail Roboz, MD, discussed how clinicians can lead patients with AML down the correct treatment path.
During the Great Debates &...
07/17/2020
Oncology
Conference Insider
Better Therapies Leading to Improved Outcomes for Transplant-Ineligible Patients With MM
07/17/2020
At the Great Debates & Updates in Hematologic Malignancies, Jonathan Kaufman, MD, discussed the standard front-line treatment approach for transplant-ineligible MM.
At the Great Debates & Updates in Hematologic Malignancies, Jonathan Kaufman, MD, discussed the standard front-line treatment approach for transplant-ineligible MM.
At the Great Debates & Updates...
07/17/2020
Oncology
Tremendous Advances in Myeloma for 2020
Videos
Tremendous Advances in Myeloma for 2020
06/16/2020
Joseph Mikhael, MD, talks about what attendees can expect from the myeloma session at this year's virtual Great Debates & Updates in Hematologic Malignancies.
Joseph Mikhael, MD, talks about what attendees can expect from the myeloma session at this year's virtual Great Debates & Updates in Hematologic Malignancies.
Joseph Mikhael, MD, talks about...
06/16/2020
Oncology
Elias Jabbour, MD, to Debate on Approaches for Treating Relapsed ALL
Videos
Elias Jabbour, MD, to Debate on Approaches for Treating Relapsed ALL
06/15/2020
Dr Jabbour will be presenting on the management of patients with Ph+ and Ph-like ALL and taking part in a debate on approaches for the treatment of patients with relapsed ALL.
Dr Jabbour will be presenting on the management of patients with Ph+ and Ph-like ALL and taking part in a debate on approaches for the treatment of patients with relapsed ALL.
Dr Jabbour will be presenting on...
06/15/2020
Oncology
Gail Roboz, MD, Hints at Topics in AML, ALL Being Debated and Addressed
Videos
Gail Roboz, MD, Hints at Topics in AML, ALL Being Debated and Addressed
06/14/2020
Dr Roboz gives attendees a taste of what's to come at this year's virtual Great Debates & Updates in Hematologic Malignancies.
Dr Roboz gives attendees a taste of what's to come at this year's virtual Great Debates & Updates in Hematologic Malignancies.
Dr Roboz gives attendees a taste...
06/14/2020
Oncology
Contemporary Topics in the Treatment of Hematologic Malignancies
Videos
Contemporary Topics in the Treatment of Hematologic Malignancies
06/13/2020
Agner Paner, MD, will address updates in supportive care for patients with multiple myeloma at the virtual 2020 Great Debates & Updates in Hematologic Malignancies.
Agner Paner, MD, will address updates in supportive care for patients with multiple myeloma at the virtual 2020 Great Debates & Updates in Hematologic Malignancies.
Agner Paner, MD, will address...
06/13/2020
Oncology
Treatment Approaches for Aggressive Myeloproliferative Neoplasms
Videos
Treatment Approaches for Aggressive Myeloproliferative Neoplasms
05/28/2020
Ruben Mesa, MD, FACP, explains current and emerging therapy options for patients with myeloproliferative neoplasms.
Ruben Mesa, MD, FACP, explains current and emerging therapy options for patients with myeloproliferative neoplasms.
Ruben Mesa, MD, FACP, explains...
05/28/2020
Oncology
Therapeutic Approaches for the Patient with Relapsed Myeloma
Videos
Therapeutic Approaches for the Patient with Relapsed Myeloma
05/12/2020
Keith Stewart, MD, ChB, discusses therapeutic approaches for patients with early relapse of MM.
Keith Stewart, MD, ChB, discusses therapeutic approaches for patients with early relapse of MM.
Keith Stewart, MD, ChB,...
05/12/2020
Oncology
Treatment of Chronic Idiopathic Myelofibrosis
Videos
Treatment of Chronic Idiopathic Myelofibrosis
05/08/2020
Ruben Mesa, MD, FACP, provides an update on therapy options for the treatment of chronic idiopathic myelofibrosis. 
Ruben Mesa, MD, FACP, provides an update on therapy options for the treatment of chronic idiopathic myelofibrosis. 
Ruben Mesa, MD, FACP, provides...
05/08/2020
Oncology
Approaching MRD in Multiple Myeloma
Videos
Approaching MRD in Multiple Myeloma
05/07/2020
Thomas Martin, MD, discusses the evolution of minimal residual disease testing in multiple myeloma and whether or not it is ready for prime time.
Thomas Martin, MD, discusses the evolution of minimal residual disease testing in multiple myeloma and whether or not it is ready for prime time.
Thomas Martin, MD, discusses the...
05/07/2020
Oncology
Benefits and Risks of Cell Therapies for Relapsed/Refractory MCL
Videos
Benefits and Risks of Cell Therapies for Relapsed/Refractory MCL
04/24/2020
Mehdi Hamadani, MD, weighs the pros and cons of allogeneic stem cell transplant and CAR-T therapy as salvage options for patients with MCL.
Mehdi Hamadani, MD, weighs the pros and cons of allogeneic stem cell transplant and CAR-T therapy as salvage options for patients with MCL.
Mehdi Hamadani, MD, weighs the...
04/24/2020
Oncology
Who Should Receive CAR-T Therapy for Lymphoma?
Videos
Who Should Receive CAR-T Therapy for Lymphoma?
03/25/2020
Lauren Pinter-Brown, MD, FACP, explains which patients with lymphoma should be referred to receive CAR T-cell therapy. 
Lauren Pinter-Brown, MD, FACP, explains which patients with lymphoma should be referred to receive CAR T-cell therapy. 
Lauren Pinter-Brown, MD,...
03/25/2020
Oncology
What is the Best Treatment Approach for Patients With Relapsed/Refractory FL?
Videos
What is the Best Treatment Approach for Patients With Relapsed/Refractory FL?
03/11/2020
Elizabeth Brem, MD, argues in favor of chemotherapy and or stem cell transplant-based regimens to treat relapsed/refractory FL.
Elizabeth Brem, MD, argues in favor of chemotherapy and or stem cell transplant-based regimens to treat relapsed/refractory FL.
Elizabeth Brem, MD, argues in...
03/11/2020
Oncology
Treatment Approaches in Systemic Marginal Zone Lymphoma
Videos
Treatment Approaches in Systemic Marginal Zone Lymphoma
03/07/2020
Elizabeth Brem, MD, gives an overview of current treatment options for MZL.
Elizabeth Brem, MD, gives an overview of current treatment options for MZL.
Elizabeth Brem, MD, gives an...
03/07/2020
Oncology
Novel Therapeutic Approaches in CLL
Videos
Novel Therapeutic Approaches in CLL
03/07/2020
Michael Choi, MD, discusses novel approaches for the treatment of patients with CLL.
Michael Choi, MD, discusses novel approaches for the treatment of patients with CLL.
Michael Choi, MD, discusses...
03/07/2020
Oncology
Emerging Therapies for Relapsed/Refractory MM
Videos
Emerging Therapies for Relapsed/Refractory MM
03/07/2020
Thomas Martin, MD, discusses emerging treatment options for patients with relapsed/refractory MM.
Thomas Martin, MD, discusses emerging treatment options for patients with relapsed/refractory MM.
Thomas Martin, MD, discusses...
03/07/2020
Oncology
New Approaches to Upfront Treatment of MCL
Videos
New Approaches to Upfront Treatment of MCL
03/07/2020
Kami Maddocks, MD, talks about what’s new in the upfront treatment landscape for MCL.
Kami Maddocks, MD, talks about what’s new in the upfront treatment landscape for MCL.
Kami Maddocks, MD, talks about...
03/07/2020
Oncology
Treating Smoldering Myeloma: Watch and Wait or Early Intervention?
Videos
Treating Smoldering Myeloma: Watch and Wait or Early Intervention?
03/07/2020
Peter Voorhees, MD, argues in favor of early intervention when treating patients with smoldering myeloma.
Peter Voorhees, MD, argues in favor of early intervention when treating patients with smoldering myeloma.
Peter Voorhees, MD, argues in...
03/07/2020
Oncology
Frontline Therapy for Transplant Ineligible Patients with MM
Videos
Frontline Therapy for Transplant Ineligible Patients with MM
03/07/2020
Keith Stewart, MD, ChB, discusses treatment options for newly diagnosed patients with myeloma ineligible for transplant.
Keith Stewart, MD, ChB, discusses treatment options for newly diagnosed patients with myeloma ineligible for transplant.
Keith Stewart, MD, ChB,...
03/07/2020
Oncology
Videos
Michael R. Savona, MD, Discusses Diagnosis and Treatment Options for CMML
06/27/2019
Michael R. Savona, MD, explains some of the challenges with diagnosing chronic myelomonocytic leukemia (CMML) and treatment options that are currently available and being studied for these patients.
Michael R. Savona, MD, explains some of the challenges with diagnosing chronic myelomonocytic leukemia (CMML) and treatment options that are currently available and being studied for these patients.
Michael R. Savona, MD, explains...
06/27/2019
Oncology
Videos
Jacqueline C. Barrientos, MD, MS, Explains the Rationale for Using Combination Therapies in CLL
06/18/2019
Jacqueline C. Barrientos, MD, MS, explains why combining therapies is beneficial for the treatment of patients with CLL.
Jacqueline C. Barrientos, MD, MS, explains why combining therapies is beneficial for the treatment of patients with CLL.
Jacqueline C. Barrientos, MD,...
06/18/2019
Oncology
Videos
MRD Assessment in Patients With Multiple Myeloma
05/09/2019
Thomas G. Martin, MD, discusses MRD assessment in patients with multiple myeloma and how it may be able to influence therapy selection for these patients.
Thomas G. Martin, MD, discusses MRD assessment in patients with multiple myeloma and how it may be able to influence therapy selection for these patients.
Thomas G. Martin, MD, discusses...
05/09/2019
Oncology
Videos
New Therapies Making a Big Impact in ALL
04/08/2019
Daniel A. Pollyea, MD, MS, discusses novel therapies for ALL and how they are changing clinical practice.
Daniel A. Pollyea, MD, MS, discusses novel therapies for ALL and how they are changing clinical practice.
Daniel A. Pollyea, MD, MS,...
04/08/2019
Oncology
Videos
The Importance of Sequencing Monotherapy in CLL
04/06/2019
Jacqueline C. Barrientos, MD, MS, explains the importance of sequencing monotherapy in chronic lymphocytic leukemia.
Jacqueline C. Barrientos, MD, MS, explains the importance of sequencing monotherapy in chronic lymphocytic leukemia.
Jacqueline C. Barrientos, MD,...
04/06/2019
Oncology
Videos
Richard R. Furman, MD, Discusses Ibrutinib Versus FCR for Patients With CLL
04/06/2019
Richard R. Furman, MD, discusses ibrutinib compared with the standard chemoimmunotherapeutic regimen of intravenous fludarabine, cyclophosphamide, and rituximab, for patients with CLL.
Richard R. Furman, MD, discusses ibrutinib compared with the standard chemoimmunotherapeutic regimen of intravenous fludarabine, cyclophosphamide, and rituximab, for patients with CLL.
Richard R. Furman, MD, discusses...
04/06/2019
Oncology
Videos
Emerging Immunotherapies and the Future of Multiple Myeloma Treatment
04/05/2019
Thomas G. Martin, MD, discusses promising immunotherapies in the pipeline for multiple myeloma and how they will affect the future treatment of this disease.
Thomas G. Martin, MD, discusses promising immunotherapies in the pipeline for multiple myeloma and how they will affect the future treatment of this disease.
Thomas G. Martin, MD, discusses...
04/05/2019
Oncology
News
Update on Upfront and Maintenance Therapy in Follicular Lymphoma
03/23/2019
John P. Leonard, MD, presented an update on upfront and maintenance therapy in follicular lymphoma at the 2019 Great Debates and Updates in Hematologic Malignancies meeting.
John P. Leonard, MD, presented an update on upfront and maintenance therapy in follicular lymphoma at the 2019 Great Debates and Updates in Hematologic Malignancies meeting.
John P. Leonard, MD, presented...
03/23/2019
Oncology
Videos
Influx of New Therapies Exciting for Future of AML Treatment
03/23/2019
Daniel A. Pollyea, MD, MS, discusses all the recent drug approvals in AML and how they are changing clinical practice.
Daniel A. Pollyea, MD, MS, discusses all the recent drug approvals in AML and how they are changing clinical practice.
Daniel A. Pollyea, MD, MS,...
03/23/2019
Oncology
Videos
When to Consider Second Autologous Transplant for Patients With Relapsed Multiple Myeloma
03/22/2019
Andrew J. Cowan, MD, explains when physicians should consider a second autologous stem cell transplant for patients with relapsed multiple myeloma.
Andrew J. Cowan, MD, explains when physicians should consider a second autologous stem cell transplant for patients with relapsed multiple myeloma.
Andrew J. Cowan, MD, explains...
03/22/2019
Oncology
Novel Small Molecule Inhibitors Show Promise in the Treatment of Multiple Myeloma
03/22/2019
Joseph Mikhael, MD, MEd, FRCPC, discussed novel small molecule inhibitors in multiple myeloma.
Joseph Mikhael, MD, MEd, FRCPC, discussed novel small molecule inhibitors in multiple myeloma.
Joseph Mikhael, MD, MEd, FRCPC,...
03/22/2019
Oncology
Videos
Great Debates and Updates in Hematologic Malignancies 2019: What to Expect
02/25/2019
Joseph Mikhael, MD, shares some insight about what to expect at this year’s meeting.
Joseph Mikhael, MD, shares some insight about what to expect at this year’s meeting.
Joseph Mikhael, MD, shares some...
02/25/2019
Oncology
News
Three-Drug Regimens Considered Standard in Multiple Myeloma Salvage Therapy
04/26/2018
Suzanne Lentzsch, MD, PhD, presented data that three drug regimens should be considered standard for myeloma salvage therapy.
Suzanne Lentzsch, MD, PhD, presented data that three drug regimens should be considered standard for myeloma salvage therapy.
Suzanne Lentzsch, MD, PhD,...
04/26/2018
Oncology

Advertisement

About

At Great Debates and Updates in Hematologic Malignancies, nationally recognized thought leaders take opposing sides on clinical—and sometimes controversial—topics currently disrupting the practice of hematology and oncology.

Through comprehensive review of the latest clinical advancements in hematologic malignancies, robust audience engagement, and ample discussion, participants will leave equipped with practical implications and applications to put into practice immediately.

Platinum Sponsors

johnson & johnson

 

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use